Trial Profile
A randomized, double-blind, Phase II/III study of JR-013 in the patients with renal anemia receiving hemodialysis treatment
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 30 May 2016
Price :
$35
*
At a glance
- Drugs Epoetin kappa (Primary)
- Indications Anaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Kissei Pharmaceutical
- 18 Jun 2015 New trial record